Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells

Abstract

CD4+ and CD8+ T cells are key components of immune response against tumors and viruses. Many techniques have been used to clone and expand these cells in vitro for purposes of immunotherapy. Here, we describe an improved method to obtain large quantities of tumor and virus-specific human CD4+ and CD8+ T-cell clones. T cells derived from peripheral blood mononuclear cells (PBMCs) of healthy donors were stimulated several times by peptide pulsed monocyte-derived mature dendritic cells (DCs) in the presence of exogenous cytokines. T cells specific for influenza or melanoma antigens were detected by IFN-γ intracellular staining and were cloned by limiting dilution. Specific polyclonal T-cell populations were derived for all epitopes presented by mature DCs. Nine different populations were cloned and clones were raised from eight of them. Clonality was verified by HLA/peptide tetramer staining. With additional rounds of stimulation after the cloning procedure, it was possible to obtain from 10⁹ to 10¹² of each clone. Furthermore, clones could be maintained in culture in the presence of IL-2 for at least 1 month without losing their antigen-specific reactivity (e.g. cytokine secretion, cytolytic activity and proliferation). Importantly, a majority of the CD8+ T-cell clones recognized endogenously processed antigens. This method is of value for the purposes of adoptive anti-virus or anti-tumor immunotherapy.

Introduction

CD8+ T cells are critical components in immune responses to infections and tumors. They differentiate into cytotoxic T lymphocytes (CTLs) and acquire the capacity to lyse virus or tumor antigen-expressing cells. Activation of CD8+ T cells requires two steps. First, the presentation of antigenic peptides on professional antigen-presenting cells (pAPCs), such as dendritic cells (DCs). Second, helper function provided by CD4+ T cells via secretion of cytokines that promote CD8+ T-cell growth and differentiation, and activation of DCs through CD40 Ligand (CD40-L)-CD40 interactions.

Adoptive transfer of virus or tumor-specific CTL clones is one promising approach to treat viral infection and certain cancers, as shown in animal models Rouse et al., 1972, Melief and Kast, 1995. In humans, it was shown that injections of cytomegalovirus (CMV) and Epstein-Barr virus (EBV)-specific T-cell clones or lines into patients who underwent an allogeneic bone marrow transplant appear to have a protective effect against herpes virus-associated diseases Walter et al., 1995, Rooney et al., 1998. Furthermore, in HIV patients, injections of HIV-specific CTL clones result in a temporary decrease of the number of HIV-infected CD4+ T cells (Brodie et al., 1999). Only one report to date described the adoptive transfer of tumor-specific CTL clones to a melanoma patient (Yee et al., 2000). The authors showed that injections of Melan-A/MART-1-specific CTL clones induce rejection of Melan-A/MART1-expressing melanoma cells.

Since the original report describing the cloning of human T cells (Bach et al., 1979), we and others have developed different approaches to amplify and clone antigen-specific T cells Weyand et al., 1986, Riddell and Greenberg, 1990, Dunbar et al., 1999, Gervois et al., 2000. Here, we describe a method to obtain both viral (Influenza A matrix protein (MP) and Influenza A hemagglutinin (HA)) and tumor (Melan-A/MART1, gp100, tyrosinase and MAGE-3)-specific CD4+ and/or CD8+ T-cell clones from peripheral blood mononuclear cells (PBMCs) of healthy donors after one or several stimulations with peptide pulsed autologous mature DCs. This method is highly reproducible and efficient. Furthermore, large quantities of T-cell clones can be obtained, the majority of which are able to recognize naturally presented antigens. This procedure may be useful for adoptive T-cell immunotherapy.